大血管闭塞卒中血管内再通后动脉内溶栓的系统综述与荟萃分析
该系统综述与荟萃分析纳入6项随机对照试验共1985例大血管闭塞急性缺血性卒中患者,评估血管内再通后动脉内溶栓的疗效与安全性。结果显示动脉内溶栓组90天mRS 0-1比例更高(RR 1.25,95%CI 1.11-1.41),而mRS 0-2、90天全因死亡、症状性颅内出血及任何颅内出血均无显著差异。
要点
- 血管内再通后动脉内溶栓可提高90天mRS 0-1比例。
- 动脉内溶栓未增加90天死亡或颅内出血风险。
- 90天mRS 0-2比例两组间无显著差异。
核心结论
- 大血管闭塞急性缺血性卒中患者血管内再通后行动脉内溶栓可额外改善功能结局,且不增加死亡或颅内出血风险。
研究设计与样本
- 研究级系统综述与荟萃分析,检索PubMed、Embase、CENTRAL和ClinicalTrials.gov从建库至2025年2月8日。
- 仅纳入报告血管内再通后动脉内溶栓疗效与安全性的随机对照试验,共纳入6项RCT、1985例初始入组患者。
- 采用Cochrane偏倚风险2工具评估偏倚风险,使用随机效应模型进行荟萃分析,方案注册于PROSPERO(CRD42025639519)。
主要发现
- 动脉内溶栓组90天mRS 0-1比例高于对照组(RR 1.25,95%CI 1.11-1.41)。
- 两组90天mRS 0-2比例无显著差异(RR 1.04,95%CI 0.96-1.13)。
- 两组90天全因死亡率无显著差异(RR 1.00,95%CI 0.83-1.21)。
- 两组症状性颅内出血无显著差异(RR 1.14,95%CI 0.76-1.70)。
- 两组任何颅内出血无显著差异(RR 1.16,95%CI 0.98-1.37)。
关键数值与推荐
- 主要结局为90天mRS 0-1比例,动脉内溶栓组RR 1.25(95%CI 1.11-1.41)。
- 90天mRS 0-2比例RR 1.04(95%CI 0.96-1.13)。
- 90天全因死亡率RR 1.00(95%CI 0.83-1.21)。
- 症状性颅内出血RR 1.14(95%CI 0.76-1.70)。
- 任何颅内出血RR 1.16(95%CI 0.98-1.37)。
临床怎么用
- 对于大血管闭塞急性缺血性卒中血管内再通成功的患者,可考虑辅助动脉内溶栓以改善90天功能独立比例。
- 决策时需结合患者个体情况,现有证据未显示动脉内溶栓增加死亡或颅内出血风险。
局限性
- 纳入研究数量较少(6项RCT),样本量有限。
- 研究级荟萃分析无法调整患者个体水平混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: This systematic review and meta-analysis aims to evaluate the treatment effects of intra-arterial thrombolysis (IAT) after endovascular recanalization in patients with acute ischemic stroke (AIS) due to large vessel occlusion (LVO). Endovascular recanalization is the standard treatment for large vessel occlusion (LVO) stroke. Despite successful reperfusion after thrombectomy, fewer than half of the patients regain functional independence at 90 days, highlighting the potential role of impaired microcirculation in poor neurologic outcomes. The efficacy and safety of intra-arterial thrombolysis (IAT) after endovascular recanalization remains controversial. This systematic review and meta-analysis aims to evaluate the treatment effects of IAT after endovascular recanalization in patients with acute ischemic stroke (AIS) due to LVO. METHODS: We conducted a study-level systematic review and meta-analysis based on PubMed, Embase, CENTRAL, and ClinicalTrials.gov from database inception to February 8, 2025. Only randomized controlled trials (RCTs) reporting the efficacy and safety of IAT after endovascular recanalization in large vessel occlusion stroke were included. The risk of bias of the included studies was assessed using the Risk of Bias 2 tool. The pooled data were analyzed using a random-effects meta-analysis. Our primary outcome was the proportion of patients with modified Rankin Scale (mRS) scores 0-1 at 90 days. Other outcomes included the proportion of patients with mRS scores 0-2 at 90 days, all-cause mortality at 90 days, and symptomatic intracranial hemorrhage and any intracranial hemorrhage within 48 hours. The study protocol was registered on PROSPERO (CRD42025639519). RESULTS: A total of 6 RCTs with 1,985 initially enrolled patients were included in the analysis. A higher proportion of mRS scores 0-1 at 90 days was observed in the IAT group (risk ratio [RR] 1.25, 95% CI 1.11-1.41). No significant differences were found in the proportion of mRS scores 0-2 at 90 days (RR 1.04, 95% CI 0.96-1.13) between the groups. Regarding safety outcomes, 90-day all-cause mortality (RR 1.00, 95% CI 0.83-1.21), symptomatic intracranial hemorrhage (RR 1.14, 95% CI 0.76-1.70), and any intracranial hemorrhage (RR 1.16, 95% CI 0.98-1.37) were similar in the IAT group and control group. DISCUSSION: Among patients with AIS due to LVO, IAT after endovascular recanalization adds additional benefits to functional outcomes, with no increased risk of death or intracranial hemorrhage.
引用
- Jiang X, Zhao Z, Zhang Y, et al. Intra-Arterial Thrombolysis Following Endovascular Recanalization for Large Vessel Occlusion Stroke: A Systematic Review and Meta-Analysis. Neurology. 2025. PMID: 40577652. doi:10.1212/WNL.0000000000213842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。